RNA

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

Retrieved on: 
Tuesday, March 5, 2024

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated.
  • Initial data are expected in the second quarter of 2024.
  • SOLSTICE is a Phase 2 multi-center, open-label trial designed to evaluate the safety, tolerability, and efficacy of tobevibart and elebsiran in adult participants (age 18 to 69) with CHD infection receiving nucleot(s)ide reverse transcriptase inhibitor therapy.
  • Depending on the cohort, trial participants are receiving multiple doses of tobevibart and elebsiran as either monotherapy or in combination administered via subcutaneous injection for up to 88 weeks.

Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Retrieved on: 
Tuesday, March 5, 2024

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline.
  • “The latest findings across our HIV pipeline showcase the potential of multiple candidates to help transform HIV management,” said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences.
  • It is estimated that up to 10% of people with HIV take a complex treatment regimen, defined as 2 or more pills each day.
  • Results showed that all three treatment groups had robust virologic suppression at six months, with consistently low viral loads throughout the study.

EnPlusOne Biosciences to Address Advances in the Enzymatic Synthesis of RNA at the 11th Annual Oligo Networking Conference

Retrieved on: 
Monday, March 4, 2024

EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that Dan Ahlstedt, COO, will be presenting the company’s ezRNA™ platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage (UK) campus on March 5, 2024.

Key Points: 
  • EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that Dan Ahlstedt, COO, will be presenting the company’s ezRNA™ platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage (UK) campus on March 5, 2024.
  • The two-day event will feature speakers from companies across life sciences discussing opportunities and challenges associated with the use of oligonucleotides in R&D and manufacturing by biopharmaceutical companies.
  • Mr. Ahlstedt’s presentation will highlight recent technical developments, and upcoming milestones, on the company’s proprietary enzymatic RNA oligonucleotide synthesis technology, as part of the Innovation in Manufacturing session at the event.
  • This community, from the beginning, has been supportive of our mission to deliver sustainable RNA at scale.

Immunis.AI Announces Publication, in The Journal of Urology, of Results from Blood-Based Immune Profiling Study for Prostate Cancer Patients

Retrieved on: 
Friday, March 1, 2024

The results validate the ability of the platform to accurately stratify risk for patients with diagnosed prostate cancer.

Key Points: 
  • The results validate the ability of the platform to accurately stratify risk for patients with diagnosed prostate cancer.
  • “One of the big challenges in prostate cancer management is distinguishing those patients with early prostate cancer who are appropriate for active surveillance from those who need to be aggressively treated.
  • In the study, peripheral blood samples were collected from 706 subjects with confirmed prostate cancer based on positive biopsy.
  • Using AI predictive modeling, the normalized immune profile of each patient was evaluated against known immune signatures for indolent or aggressive prostate cancer.

Celanese Announces Commercial Launch of Glaukos' iDose® TR (Travoprost Intracameral Implant) Using Celanese's VitalDose® Ethylene Vinyl Acetate (EVA)

Retrieved on: 
Thursday, February 29, 2024

Sustained delivery of therapeutics provides an important approach in addressing non-compliance and improving treatment outcomes.

Key Points: 
  • Sustained delivery of therapeutics provides an important approach in addressing non-compliance and improving treatment outcomes.
  • With iDose® TR and the VitalDose® EVA, there is now the opportunity to provide continuous dosing which can improve patient compliance and address adherence issues.
  • iDose® TR was approved on the basis of two pivotal trials (1,150 subjects randomized across both trials), which demonstrated safety and efficacy.
  • Glaukos used the VitalDose® EVA to create a nanoporous membrane for travoprost delivery in iDose® TR.

NTx Appoints Steven Evans as Chief Scientific Officer

Retrieved on: 
Tuesday, February 27, 2024

Nature’s Toolbox (NTx) a life sciences company building next generation platforms to manufacture RNA and protein, today announced the appointment of Steven Evans, Ph.D. as Chief Scientific Officer and Senior Vice President of R&D.

Key Points: 
  • Nature’s Toolbox (NTx) a life sciences company building next generation platforms to manufacture RNA and protein, today announced the appointment of Steven Evans, Ph.D. as Chief Scientific Officer and Senior Vice President of R&D.
  • View the full release here: https://www.businesswire.com/news/home/20240227674119/en/
    NTx has appointed Steven Evans, Ph.D. as Chief Scientific Officer and Senior Vice President of R&D.
  • At NTx, Steven will leverage his extensive skills in executive leadership, strategic planning, and cross-collaboration to drive the company’s R&D initiatives to new heights.
  • He has built an outstanding team of scientists and positioned the company for accelerated growth,” said Jamie Coffin, CEO of NTx.

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Retrieved on: 
Tuesday, February 27, 2024

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
  • “Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
  • Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer.
  • Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company.

Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

Retrieved on: 
Monday, February 26, 2024

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at a Fireside Chat hosted by Barclays 26th Annual Global Healthcare Conference in Miami, on Thursday, March 14, 2024, at 11:45 a.m. Eastern Time.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at a Fireside Chat hosted by Barclays 26th Annual Global Healthcare Conference in Miami, on Thursday, March 14, 2024, at 11:45 a.m. Eastern Time.
  • A webcast and replay of the presentation will be available on the “Investor Relations/Events” section of the Company’s website at: https://ir.arcturusrx.com/investor-calendar .

U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance

Retrieved on: 
Monday, February 26, 2024

HIV treatment resistance is permanent and irreversible, which can jeopardize future treatment options for PWH.

Key Points: 
  • HIV treatment resistance is permanent and irreversible, which can jeopardize future treatment options for PWH.
  • The M184V/I resistance mutation has been found to be present in a range (22-63%) of PWH with pre-existing resistance to nucleoside reverse transcriptase inhibitors (NRTIs) across various HIV subtypes.
  • “Clinical data have established Biktarvy as a long-term HIV treatment option for a broad range of PWH.
  • There were also zero cases of treatment-emergent resistance to Biktarvy, regardless of known or suspected pre-existing M184V/I resistance, in the final resistance analysis population.

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Retrieved on: 
Friday, February 23, 2024

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the initiation by AstraZeneca of a phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration, has triggered a $10.0 million milestone payment to Silence.

Key Points: 
  • Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the initiation by AstraZeneca of a phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration, has triggered a $10.0 million milestone payment to Silence.
  • “This represents the first clinical milestone under our collaboration with AstraZeneca and the third program to enter the clinic from our mRNAi GOLD™ platform,” said Craig Tooman, President and CEO of Silence.
  • Silence and AstraZeneca initiated a multi-target collaboration in March 2020 focused on using Silence’s proprietary mRNAi GOLD™ platform to develop siRNA therapeutics for cardiovascular, renal, metabolic and respiratory diseases.
  • Under the agreement, AstraZeneca will pay Silence an option fee of $10 million for each selected target at the point of candidate nomination.